European pharmaceutical company offers its investigational
medicinal product to a wide range of specialist medical
practitioners in the United
Kingdom
Epidiolex's Success Highlights Potential for MGC Pharma's
CannEpil®
The recent success of Epidiolex, a CBD-based epilepsy
treatment that generated $296 million
in sales in 2019, highlights the potential for MGC Pharma's
CannEpil® in the UK market. This underlines the potential of
CannEpil®, an investigational medicinal product for patients
suffering from refractory epilepsy, to make a significant impact in
the UK market.
LONDON, April 11, 2023 /PRNewswire/ -- MGC
Pharmaceuticals Ltd. (LSE: MXC), (ASX: MXC), (OTC: MGCLF), a
European based pharmaceutical company specializing in the
development and supply of affordable, ethically produced
plant-inspired medicines, announces that its proprietary product
CannEpil® is now available to patients in the UK by Named Patient
Request.
MGC Pharma's CannEpil® is an investigational medicinal product
(IMP) designed for patients suffering from refractory epilepsy,
also known as drug-resistant epilepsy. The high-CBD, low-THC
formulation is administered via an oral mucosal solution and is
currently undergoing a clinical development program. The
availability of CannEpil® in the UK follows the company's
announcement that it is providing the product for an observational
trial supported by the I am Billy Foundation.
With this development, clinicians in the UK listed on the
General Medical Council (GMC) Specialist Register can now prescribe
CannEpil®. This is a significant milestone for MGC Pharma and
patients with unmet medical needs, as it expands the company's
reach within the healthcare and life science sectors as an
innovative plant-inspired pharmaceutical company.
CannEpil® has already been prescribed to hundreds of patients
across Australia and the
Republic of Ireland over the past
three years. In 2019, it became the first product to be available
with coverage in the Republic of
Ireland under the Long Term Illness and General Medical
Services schemes.
The data collected from patients using CannEpil® will be used to
further evaluate the safety and efficacy of the drug, supporting
future submissions for marketing authorization.
Epilepsy affects approximately 50 million people worldwide, with
33% of adults and 20-25% of children suffering from refractory
epilepsy. CBD has been proven effective in reducing seizure
frequency and severity, as supported by open-label studies,
observational studies, randomized clinical trials (RCTs), and
large-scale systematic reviews.
Roby Zomer, Managing Director and
CEO of MGC Pharmaceuticals, commented: "The availability of
CannEpil® by Named Patient Request marks a momentous breakthrough
for MGC Pharma. The product will now be available to a wide cohort
of specialist medical practitioners in the UK, which is testament
to the progress we are making."
"We are extremely proud of the progress we have achieved thus
far, and we are pleased that CannEpil® has been selected as a
treatment within an observational patient trial in association with
the I am Billy Foundation. We look forward to updating the market
on the results of this trial in due course."
HTTP://MGCpharma.eu
Twitter: @MGC_Pharma
Facebook: @mgcpharmaceuticals
Logo -
https://mma.prnewswire.com/media/1780050/mgcpharma_logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/mgc-pharmas-cannepil-now-accessible-to-uk-patients-on-named-patient-request-basis-301793534.html
